North Carolina Patent of the Month – June 2024

LifeEDIT Therapeutics, Inc. is at the forefront of genetic research with its latest innovation in RNA-guided nuclease (RGN) technology. Their newly developed nucleic acid molecule, encoding an RGN polypeptide, holds immense potential for precise genome editing. This advanced molecule features a sequence identity of at least 92% to specified sequences and is adept at binding to target DNA sequences via guide RNA (gRNA).

The versatility of this invention lies in its ability to be operably linked to a heterologous promoter, enhancing its adaptability across various applications. It includes a range of configurations, from being nuclease inactive to functioning as a nickase, and can even be fused with base-editing polypeptides for targeted modifications. Moreover, the molecule can be optimized for expression in eukaryotic cells, ensuring high efficiency and effectiveness in complex biological systems.

LifeEDIT Therapeutics’ innovation doesn’t stop at individual molecules. They have also developed vectors that incorporate these nucleic acid molecules, complete with gRNA sequences for precise targeting. These vectors facilitate the delivery and expression of RGN polypeptides in host cells, enabling researchers to conduct high-precision genetic modifications. The system’s adaptability is further enhanced by the inclusion of various gRNA structures, allowing it to tackle a broad spectrum of genetic targets.

This cutting-edge technology is poised to revolutionize therapeutic and research applications by enabling detailed and accurate genetic editing. By providing tools that can create single- or double-stranded breaks in DNA, LifeEDIT Therapeutics opens new avenues for gene therapy, disease modeling, and the study of genetic diseases. Their approach promises not only to enhance our understanding of genetic mechanisms but also to pave the way for innovative treatments and interventions.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts